{
    "brief_title": "Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer",
    "phase": "Phase 2",
    "drugs": "['Apatinib', 'Paclitaxel']",
    "drugs_list": [
        "Apatinib",
        "Paclitaxel"
    ],
    "diseases": "['Triple Negative Breast Cancer']",
    "diseases_list": [
        "Triple Negative Breast Cancer"
    ],
    "enrollment": "20.0",
    "inclusion_criteria": "inclusion criteria: \n\n patients between18 and 75 Years old; \n\n patients with locally advanced breast cancer (TNM periodization:T is equal to or greater than 2,N is equal to 1,M is equal to 0) \n\n clear for immunohistochemical is that: estrogen receptor-negative (ER-), progesterone receptor-negative (PR-), the human epidermal growth factor receptor 2 is Negative ( IHC Her-2 0/+ , If ER- \u3001 PR- But Her-2 ++ , You need to do FISH/CISH Testing confirmed that Her-2 Amplification is negative); \n\n The ECOG score is between 0 to 2 points; \n\n The expected lifetime is \u22653 months; \n\n Major organ function is normal, that meet the following criteria: \n\n Blood test standards subject to: \n\n HB\u226590 g/L ; \n\n ANC\u22651.5\u00d7109 /L ; \n\n PLT\u2265100\u00d7109 /L ; \n\n Biochemical examination must meet the following criteria: \n\n TBIL\u22641.5xULN ( upper limit of normal value ) ; \n\n ALT AST\u22642.5\u00d7ULN ; \n\n Serum Cr\u22641.5\u00d7ULN And endogenous creatinine clearance rate \u226550 mL/min (Cockcroft-Gault formula ) ; \n\n the women of childbearing age must do the pregnancy test ( serum or urine ) within 7 days when they are included in the trial, And the result was negative, and during the trial and at the time of giving experimental drugs after 8 weeks using the appropriate methods of contraception; \n\n no difficulty in swallowing, swallowing oral medications; \n\n the participants volunteered to join this study should sign the informed consent forms, have better compliance, work in with the follow-up \n\n ",
    "exclusion_criteria": ": \n\n patients with pregnancy or lactation; \n\n inflammatory breast cancer patients; \n\n patients with several factors affecting medication (for example, inability to swallow, such as nausea, vomiting, chronic diarrhea, and bowel obstruction); \n\n injury or pathologic fracture; \n\n people with high blood pressure and antihypertensive drug treatment could not be reduced to within the normal range (systolic >140 mmHg, diastolic pressure >90 mmHg) ; \n\n with \u2171 grade myocardial ischemia, poor control of arrhythmias or myocardial infarction (including QTc interval men \u2265450 Ms, female \u2265470 Ms); \n\n according to NYHA standard \u2172 \n\n \u2173 -class heart insufficiency or heart ultrasound: LVEF(left ventricular ejection fraction) <50%; \n\n the past 6 months have gastrointestinal bleeding within history or definite gastrointestinal bleeding, such as: risk of bleeding oesophageal varicose ulcer lesions, fecal occult blood, local activities \u2265 (++) Into groups; such as the fecal occult blood (+), requires endoscopy; \n\n prior to participating in the study of 28 days abdominal fistula, perforation of the gastrointestinal tract and abdominal abscesses; \n\n positive patients of urinary protein (urine protein 2+ or above, or 24 -hour urine protein > 1.0g); \n\n distant metastasis of patients with symptoms or are not controlled; \n\n expected lifetime < 3 months; \n\n into the group before 28 days to accept other anticancer treatment; \n\n other information: dysfunction of blood coagulation (INR>1.5 or prothrombin time ( PT )> ULN+4 Seconds); Anticoagulant therapy are receiving antithrombotic or infection who needed intravenous antibiotics; previously receiving bevacizumab treatment or other anti- VEGF TKI Drug treatment, with a second tumor (except basal cell carcinoma and cervical carcinoma in situ); \n\n a history of immunodeficiency, including HIV testing positive, or suffer from other acquired, congenital immune deficiency disease or have a history of organ transplantation;",
    "brief_summary": "The purpose of this study is to evaluate the efficacy and safety of apatinib in patient with TNBC",
    "NCT_ID": "NCT03348098"
}